Overview

Safety and Efficacy of PG101 for Dry Eye Syndrome

Status:
Completed

Trial end date:
2014-01-01

Target enrollment:

Participant gender:

Summary

To evaluate the safety and efficacy of 0.25% PG101 and 1.0% PG101 topical gel suspension compared to placebo when administered two times daily for 14 days in subjects diagnosed with dry eye syndrome

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Rhodes Pharmaceuticals, L.P.

Collaborator:

ORA, Inc.